Our clinical programs
Cantargia leads clinical studies for cancer and autoimmune diseases through projects nadunolimab (CAN04) and CAN10.
cantargia.comCrawled Nov 11, 2026
Cantargia leads clinical studies for cancer and autoimmune diseases through projects nadunolimab (CAN04) and CAN10.
Cantargia seeks to enhance the lives of patients with serious diseases through scientific innovation.
Cantargia holds global patents for antibody-based treatments, including candidates nadunolimab and CAN10.
Cantargia’s pipeline includes nadunolimab (CAN04) for cancer treatment and CAN10 for autoimmune diseases.
Cantargia aims to improve treatment methods for cancer and autoimmune conditions through scientific excellence.
Cantargia’s research on IL1RAP-targeting antibodies explores new paths for cancer therapy and autoimmune/inflammatory disease treatment.
Cantargia offers a media library with high-resolution images of its leadership and official logo.
Cantargia provides contact details for media inquiries and press resources.
Cantargia’s board combines deep scientific expertise with strategic leadership to shape the future of biotechnology.
Cantargia’s leadership merges scientific excellence with strategic vision to drive biotech innovation.
Cantargia is a Swedish biotech company developing next-generation treatments for cancer, autoimmune, and inflammatory diseases.
Cantargia focuses on sustainability, addressing environmental, social, and governance aspects to promote a sustainable future in biotech.
Cantargia provides contact information for inquiries and questions.
Cantargia expands its bispecific antibody CAN14 to target IL-17 alongside its existing IL1RAP focus. The company develops antibody-based therapeutics in clinical stages. This marks the second validated target for CAN14, broadening potential applications in autoimmune or inflammatory diseases.
Cantargia appoints Monic Stuart as its new chief medical officer. The biotechnology company, based in Sweden, formalizes the role effective immediately. Stuart brings medical leadership to support Cantargia’s drug development pipeline.
Cantargia AB releases its first-quarter 2026 financial results, detailing performance metrics and operational updates for investors. The Swedish biotech company, listed on Nasdaq Stockholm, provides insights into its ongoing projects and revenue trends. The report follows standard quarterly disclosures for publicly traded firms in the healthcare sector.
Cantargia reports early findings from its Phase 1b/2a trial testing nadunolimab, an antibody-based therapy targeting IL1RAP. The study evaluates nadunolimab combined with azacitidine for high-risk myelodysplastic syndrome (MDS) and with azacitidine plus venetoclax for acute myelogenous leukemia (AML). Results are drawn from ongoing clinical assessments of the drug’s safety and efficacy in these blood cancer indications.
Cantargia AB releases its full-year financial report for 2025, detailing performance metrics and operational updates. The document is accessible via the company’s investor relations webpage. Cantargia operates in the biopharmaceutical sector, focusing on antibody-based therapies.